Feature Gamida Cell shifts focus to NiCord stem cell product By Len Zehr Closely held Gamida Cell has shifted its focus to its second-generation stem cell product, NiCord, for the treatment of hematological malignancies and non-malignant hematological diseases in the wake of an... March 4, 2014